Showing results (861-870 of 1,038) with videos related to

Sort By:
Pageof 104
Surgery|May 14, 2023
Falling from new heights: Traumatic fracture burden and resource utilization after border wall height increaseEmma E Williams, Cooper B Haaland, Laura N Haines, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaManish A Shah, Ramesh K Ramanathan, David H Ilson, et al.
Pacing and Clinical Electrophysiology : PACE|January 4, 2001
High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutationH M Bécane, G Bonne, S Varnous, et al.
Science Signaling|September 26, 2013
Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targetsMartin L Miller, Evan J Molinelli, Jayasree S Nair, et al.
Oncotarget|July 20, 2019
Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivoElgilda Musi, Gary K Schwartz, Jae Hyuk Yoo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeksS Sharma, N Kemeny, G K Schwartz, et al.
Clinical Trials (London, England)|February 4, 2020
Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patientsGrace C Hillyer, Melissa Beauchemin, Dawn L Hershman, et al.
European Journal of Heart Failure|August 11, 2000
Familial dilated cardiomyopathy: clinical features in French familiesL Mangin, P Charron, F Tesson, et al.
The Journal of Trauma|May 26, 2011
Combat versus civilian open tibia fractures: the effect of blast mechanism on limb salvageJay J Doucet, Michael R Galarneau, Bruce M Potenza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumorsGary K Schwartz, Eileen O'Reilly, David Ilson, et al.
Pageof 104